At the 8th China International Import ExpoAt the China International Import Expo (hereinafter referred to as "CIIE"), GlaxoSmithKlineGSK successfully invited several senior experts, scholars, and non-profit partners in the field of rheumatology and immunology to gather together to exchange ideas on topics such as disease awareness, patient support, and chronic disease management of systemic lupus erythematosus (SLE). The aim was to improve public scientific understanding, improve the living environment of patients, and help patients regain confidence in life.

Leveraging the powerful enabling effect of the China International Import Expo

　　Data shows that systemic lupus erythematosus (SLE) is a chronic autoimmune connective tissue disease that can cause damage to multiple organs and tissues, including the kidneys, cardiovascular system, lungs, digestive system, blood system, and eyes, and significantly increases the risk of death. Currently, there are over one million lupus patients in China, primarily women of childbearing age. With the continuous improvement in lupus diagnosis and treatment in my country in recent years, the survival rate of lupus patients has significantly improved. Faced with the increasingly chronic nature of SLE, patients' needs have shifted from simply "surviving" to "living longer and better."

　　Yu Huiming, Vice President and General Manager of GSK China, stated, "GSK is a loyal partner of the China International Import Expo (CIIE). Over the years, leveraging the powerful enabling effect of the CIIE, we have been able to more efficiently collaborate with all sectors of society to accelerate innovative drug development .""Making things accessible, extending the reach of care to patients in dire need."

　　Zhang Ning, Vice President of GSK and Head of Specialty Drugs Business Unit in China, stated, “GSK has been deeply involved in the lupus field for over a decade, and the indications for its belimumab are constantly expanding. This reflects our high regard for the needs of Chinese patients and is also an example of how GSK can collaborate with various parties and share opportunities. Focusing on the unmet needs of over one million lupus patients in China, in the future, while continuously introducing innovative treatment options and expanding new indications to improve the prognosis of lupus patients, GSK will continue to dedicate itself to comprehensively improving the standardized diagnosis, treatment, and management of lupus in China, and helping patients ‘regain a better life’ in multiple ways.”

　　Professor Sun Li, Director of the Department of Rheumatology at the Children's Hospital of Fudan University, stated that childhood lupus requires a full-lifecycle management approach based on "early diagnosis and treatment, and sustained achievement of treatment goals." Biologics, represented by belimumab, demonstrate their core value. Through early, precise, and continuous intervention, they effectively control disease activity, significantly reduce hormone dependence, and safeguard children's bone growth and organ development during critical periods. This not only helps reduce relapses and hospitalizations but also supports children in learning normally, enjoying sports, and smoothly reintegrating into school life, just like healthy children. It allows them to face the future fearlessly and bravely pursue their own youthful dreams.

Establish a standardized national systemic lupus erythematosus diagnosis and treatment system

　　Professor Chen Nan, a tenured professor in the Department of Nephrology at Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, stated: "After being diagnosed with lupus nephritis, patients should receive standardized treatment as early as possible and undergo long-term continuous monitoring of their condition (dynamic monitoring of urine protein, urine sediment, and kidney function, etc.). The treatment efficacy should be comprehensively evaluated in conjunction with necessary indicators such as disease activity, kidney biopsy, and biomarkers. At the same time, it is necessary to manage the disease effectively. The proportion of kidney damage caused by traditional drug treatment is very high, the progression is very rapid, and there are many complications, such as moon face, buffalo hump, cardiovascular disease, and osteoporosis. Early initiation of belimumab treatment can help patients reduce the dosage of hormones, reduce the risk of relapse, and continuously protect kidney function. I believe that with the continuous progress of medicine and the continued support of policies, the future of lupus patients will be even brighter."

　　Dr. Ke Yuxiong, Vice President and Head of Medical Affairs for China at GSK, stated, “Innovation is the cornerstone for continuously advancing the standardization and cutting-edge development of lupus treatment. We are delighted that our biologic, Benlytenda, recommended by three major guidelines, will benefit a wider range of patients thanks to the spillover effect of the China International Import Expo. However, the meaning of innovation goes far beyond research and development. In addition to continuously introducing innovative treatment options, we are also actively collaborating with China Pharmaceutical…”The National Health Development Foundation, the National Clinical Research Center for Skin and Immune Diseases, and the Shanghai Puji Rheumatology Care Center, among other organizations, are collaborating to establish a standardized national systemic lupus erythematosus (SLE) diagnosis and treatment system to help improve the prognosis of lupus patients.

　　Zheng Jiyang, Chairman of the Board of Directors of the Shanghai Puji Rheumatology Care Center, stated: "Since signing a strategic cooperation memorandum with GSK at last year's China International Import Expo, both parties have focused on disease education... "Our work in patient care, treatment, and management has yielded significant results. Looking ahead, we look forward to exploring more avenues with GSK to positively impact the lives and living conditions of the vast lupus patient population, thereby contributing to improving the quality of life for millions of lupus patients in China.

https://finance.eastmoney.com/a/202511073558114960.html